Selected Grants
Mechanisms of APOBEC3A-induced cancer evolution and cancer vulnerability
ResearchPrincipal Investigator · Awarded by Massachusetts General Hospital · 2024 - 2029Understanding and targeting the DNA replication stress in cancer cells
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2023 - 2028ASPET SURF Institutional Award
Inst. Training Prgm or CMEParticipating Faculty Member · Awarded by American Society for Pharmacology and Experimental Therapeutics · 2018 - 2028Synergistic combinatorial DNA damage response/repair inhibition and Sacituzumab Govitecan in triple-negative breast cancer
ResearchPrincipal Investigator · Awarded by Massachusetts General Hospital · 2023 - 2026Uncovering novel vulnerabilities to treat SCLC therapy resistance
ResearchCollaborator · Awarded by Lung Cancer Research Foundation · 2023 - 2025Dissecting early pathogenesis of BRCA1/2-associated cancer for risk prediction and prevention
ResearchPrincipal Investigator · Awarded by Massachusetts General Hospital · 2023 - 2025Genetic and Genomics Training Grant
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2020 - 2025Mechanisms of replication fork protection and recovery
ResearchPrincipal Investigator · Awarded by Washington University in St. Louis · 2023 - 2025Understanding and targeting RNA/transcription-dependent DNA repair in cancer cells
ResearchUnit Director · Awarded by National Institutes of Health · 2022 - 2023External Relationships
- Bristol Myers Squibb
- Chinese Biological Investigators Society
- Chinese Institute of Medical Research, Beijing
- Cold Spring Harbor Asia
- Duke -National Univeristy of Singapore
- Fusion conferences
- Institute of Life Sciences, Zhejiang University
- Jacques-Monod Conference
- National Institute of Health
- Pfizer Inc.
- Shenzhen University
- Sirrona Therapeutics, Inc
- The New Cornerstone Investigator Program
- Washington University in St. Louis
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.